viernes, 31 de mayo de 2024

Existing drug shows promise as treatment for rare genetic disorder NIH researchers find new pathways towards treatment for autoimmune polyendocrine syndrome type 1. A drug approved to treat certain autoimmune diseases and cancers successfully alleviated symptoms of a rare genetic syndrome called autoimmune polyendocrine syndrome type 1 (APS-1). Researchers identified the treatment based on their discovery that the syndrome is linked to elevated levels of interferon-gamma (IFN-gamma), a protein involved in immune system responses, providing new insights into the role of IFN-gamma in autoimmunity. The study, led by researchers at NIAID, was published today in the New England Journal of Medicine.

No hay comentarios:

Publicar un comentario